11 August 2022 | News
Latch Medical is a developer of vaccine and biologics delivery platforms
Image Credit: Shutterstock
US-based West Pharmaceutical Services has made a strategic investment in Latch Medical, a Dublin-based leader in next generation vaccine and biologics delivery technology that is pioneering a new approach to intradermal delivery.
West joins Latch Medical's existing investors Atlantic Bridge and Enterprise Ireland. West will take a minority ownership stake in Latch Medical.
Latch Medical's Pharma Latch technology offers two delivery device platforms that allow for intradermal delivery of vaccines and biologics with rapid, consistent dosing. The technology anchors securely to the skin and uses either hollow or coated microneedles to deliver and disperse vaccine and biologics payloads. The technology is a low-cost platform that can facilitate higher payloads than microneedle technologies developed in the past. It requires minimal training for clinicians to use.
As evidenced by the investment in Latch Medical, West continues to make startup investments in the medical device space to create and advance offerings that allow for care to be delivered more effectively and efficiently.